Open report — full analysis, no account required.

Sign up to generate reports and read filings that aren't on the open list.

Sign up free

Get notified when ACTU files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts
NASDAQ: ACTU ACTUATE THERAPEUTICS, INC. 8-K

Actuate Therapeutics holds routine annual meeting, elects directors and ratifies auditor

Filed May 22, 2026 · Period ending May 21, 2026 · ~1 min read

2 key changes 1 section

Key Changes

  • low

    Stockholders elected Aaron G.L. Fletcher (88.8% support) and Jason Keyes (99.8% support) as Class II directors for three-year terms through 2029 in uncontested elections.

    Item 5.07 verify on EDGAR →
  • low

    Crowe LLP ratified as independent auditor for fiscal 2026 with 99.7% approval (18,571,817 for, 50,023 against, 9,741 abstentions).

    Item 5.07 verify on EDGAR →

Summary

Actuate Therapeutics held its annual stockholder meeting on May 21, 2026, completing routine governance matters. The company elected two Class II directors to serve three-year terms expiring in 2029: Aaron G.L. Fletcher, Ph.D. and Jason Keyes. Both elections were uncontested, with Fletcher receiving 88.8% support and Keyes receiving 99.8% support from votes cast.

Stockholders also ratified the appointment of Crowe LLP as the company's independent registered public accounting firm for fiscal year 2026, with 99.7% approval. This is a procedural filing with no material impact on operations or strategy. The strong support levels across both proposals reflect normal shareholder approval for routine governance items at a clinical-stage therapeutics company.

Section-by-Section Diff

Event · Item 5.07 — Submission of Matters to a Vote of Security Holders

~300 words

Annual meeting: two Class II directors elected, auditor Crowe LLP ratified for FY2026.

1 Added
Show 1 minor / wording change
Added Director elections low

Added in current filing · verify on EDGAR →

Aaron G.L. Fletcher, Ph.D. 14,877,247 | 1,883,025 | 1,871,309 Jason Keyes | 16,727,875 | 32,397 | 1,871,309

Stockholders elected two Class II directors to three-year terms through 2029. Aaron G.L. Fletcher received 14,877,247 votes for and 1,883,025 withheld (88.8% support). Jason Keyes received 16,727,875 votes for and 32,397 withheld (99.8% support). Both elections were uncontested and passed with strong support.

Was this report useful?
View original filing on SEC.gov

Figures/quotes linked to EDGAR · Narrative written by AI · Jun 21, 2026 · How we verify